Learn More
BACKGROUND The use of proton pump inhibitors has been associated with an increased risk of hip fracture. We sought to further explore the relation between duration of exposure to proton pump inhibitors and osteoporosis-related fractures. METHODS We used administrative claims data to identify patients with a fracture of the hip, vertebra or wrist between(More)
BACKGROUNDS & AIMS Recent studies have shown an association between proton-pump inhibitor use (PPI) and hip fracture. The mechanism by which PPI use promotes the development of hip fracture is uncharacterized. Therefore, we sought to determine whether PPI use is associated with osteoporosis or accelerated bone mineral density (BMD) loss. METHODS We used(More)
OBJECTIVE We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations. METHODS Using population-based administrative data, we identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and(More)
OBJECTIVES The use of the common antidepressant class of serotonin-specific reuptake inhibitors (SSRIs) is associated with an increased risk of upper gastrointestinal bleeding (UGIB). Proton pump inhibitors (PPIs) have been demonstrated to reduce the risk of gastrointestinal bleeding secondary to other risk factors, most notably non-steroidal(More)
BACKGROUND & AIMS There are numerous gastroprotective strategies recommended for reducing the risk of upper gastrointestinal (GI) complications in long-term users of nonsteroidal anti-inflammatory drugs (NSAIDs). The relative efficacy of the different strategies alone or in combination is uncertain. METHODS We used the Manitoba Population Health Research(More)
OBJECTIVE Several studies suggest an increasing prevalence of multiple sclerosis (MS) in Canada. We aimed to validate a case definition for MS using administrative health insurance data, and to describe the incidence and prevalence of MS in Manitoba, Canada. METHODS We used provincial administrative claims data to identify persons with demyelinating(More)
BACKGROUND Although comorbidity is important in multiple sclerosis (MS), few validated methods for its assessment exist. We validated and applied administrative case definitions for several comorbidities in MS. METHODS Using provincial administrative data we identified persons with MS and a matched general population cohort. Case definitions for chronic(More)
BACKGROUND Despite the importance of comorbidity in multiple sclerosis (MS), methods for comorbidity assessment in MS are poorly developed. OBJECTIVE We validated and applied administrative case definitions for diabetes, hypertension, and hyperlipidemia in MS. METHODS Using provincial administrative data we identified persons with MS and a matched(More)
BACKGROUND While mental comorbidity is considered common in multiple sclerosis (MS), its impact is poorly defined; methods are needed to support studies of mental comorbidity. We validated and applied administrative case definitions for any mental comorbidities in MS. METHODS Using administrative health data we identified persons with MS and a matched(More)
BACKGROUND Studies suggest an altered risk of ischemic heart disease (IHD) in multiple sclerosis (MS), but data are limited. We aimed to validate and apply administrative case definitions to estimate the incidence and prevalence of IHD in MS. METHODS Using administrative data we identified persons with incident MS (MSPOP) and a matched general population(More)